# A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease

> **NCT01978548** · PHASE1 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 45 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** JNJ-54861911 10 mg
- **DRUG:** JNJ-54861911 50 mg
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01978548
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-12
- **Primary completion:** 2015-04
- **Final completion:** 2015-04
- **Target enrollment:** 45 (ACTUAL)
- **Last updated:** 2015-06-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01978548

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01978548, "A Study to Evaluate the Effects of JNJ-54861911 on Amyloid Beta Processing in Cerebrospinal Fluid and Plasma in Patients With Prodromal Alzheimer's Disease". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01978548. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*